ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Clinical trial NCT06430385 · RECRUITING
Trial details
- NCT number
- NCT06430385
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-21
- Primary completion
- 2027-09-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.